Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsPreferred Shares RepurchasedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Change in Cash (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Change in Cash for 17 consecutive years, with $4.8 million as the latest value for Q1 2026.

  • Quarterly Change in Cash rose 206.8% to $4.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Jan 2026, up 108.44% year-over-year, with the annual reading at -$35.0 million for FY2025, 96.01% down from the prior year.
  • Change in Cash for Q1 2026 was $4.8 million at PharmaCyte Biotech, up from $2.2 million in the prior quarter.
  • The five-year high for Change in Cash was $6.6 million in Q3 2023, with the low at -$17.5 million in Q3 2024.
  • Average Change in Cash over 5 years is -$3.9 million, with a median of -$3.2 million recorded in 2022.
  • Peak annual rise in Change in Cash hit 308.71% in 2023, while the deepest fall reached 1346.31% in 2023.
  • Over 5 years, Change in Cash stood at -$5.3 million in 2022, then surged by 76.5% to -$1.2 million in 2023, then crashed by 853.32% to -$11.8 million in 2024, then skyrocketed by 118.89% to $2.2 million in 2025, then surged by 113.65% to $4.8 million in 2026.
  • According to Business Quant data, Change in Cash over the past three periods came in at $4.8 million, $2.2 million, and -$2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.